By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs)9.69M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States62.04M100.00%